The International Foundation for Autoimmune & Autoinflammatory Arthritis has raised concerns about the rising costs in the federal 340B Drug Pricing Program, stating that these increases are not benefiting patients — an issue garnering attention in New York. The organization has called for urgent reforms to enhance accountability and transparency, as reported in a statement on X.
The 340B Drug Pricing Program mandates pharmaceutical manufacturers to offer discounted outpatient drugs to eligible hospitals and clinics. However, multiple analyses indicate that a significant portion of these savings does not directly reduce patient out-of-pocket expenses. Critics argue that the program has deviated from its original purpose, with reform advocates emphasizing the need for clearer rules and reporting to ensure discounts reach patients who need them.
According to the Health Resources and Services Administration, drug purchases under the 340B program have surged from approximately $6.6 billion in 2010 to over $43.9 billion in 2021, indicating a substantial increase in program spending. Despite this growth, oversight mechanisms have not expanded proportionally, raising concerns about the integrity of the program. Experts caution that without robust audits and transparency measures, it remains uncertain how much of this expansion benefits safety-net patients.
According to PhRMA’s 2025 New York fact sheet, 85% of 340B hospitals fall below the national charity-care average, even as their assets increased 38% and uncompensated care declined 29% from 2014–2022. Meanwhile, there are 12,929 arrangements with for-profit contract pharmacies, including 3,861 outside New York, signaling that 340B dollars may enrich middlemen rather than patients.
The International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), a nonprofit organization focused on improving the lives of individuals with autoimmune arthritis diseases through education, advocacy, and patient-centered policy engagement, regularly participates in federal health policy discussions. Through research partnerships and patient-focused initiatives, AiArthritis amplifies community voices concerning access and affordability issues.
